NasdaqGM:ETONPharmaceuticals
Eton Pharmaceuticals (ETON) Returns To Profit As Valuation Debate Gets Harder To Ignore
Eton Pharmaceuticals (ETON) drew investor attention on 13 August 2026 after reporting stronger second quarter earnings and a return to profitability, along with higher full year 2026 revenue guidance of at least US$145 million.
See our latest analysis for Eton Pharmaceuticals.
Eton Pharmaceuticals’ latest earnings announcement comes after a strong run in the stock, with a 30 day share price return of 49.03% and a 1 year total shareholder return of 266.88%. This adds to very large 3 and 5 year...